aTyr Pharma has aligned with the FDA on a Phase Three efzofitimod study using 5.0 mg/kg intravenous dosing every 3 weeks for patients with pulmonary sarcoidosis and restrictive lung disease. The plan matters to investors because U.S. and European submissions are targeted while future development will require additional capital.

Key Highlights

  • The planned trial will keep participants’ background treatments stable throughout the study.
  • Forced vital capacity change at week 48 will serve as the primary endpoint.
  • ATYR expects to begin study activities in the fourth quarter of 2026.
  • Efzofitimod will be evaluated in a randomized, double-blind, placebo-controlled global study for moderate to severe pulmonary sarcoidosis.

ATYR (NASDAQ: ATYR) is a major pharmaceuticals company. The company expects to begin study activities in the fourth quarter of 2026 while focusing on regulatory submissions in the United States and Europe.

Efzofitimod Study Sets 5.0 mg/kg Regimen

The global study will be randomized, double-blind, placebo-controlled and designed to evaluate efzofitimod’s efficacy and safety in moderate to severe pulmonary sarcoidosis. Participants will be assigned equally to efzofitimod or placebo, with efzofitimod administered intravenously at 5.0 mg/kg once every 3 weeks. The planned population includes patients receiving a stable oral corticosteroid dose of ≤ 5.0 mg daily and/or a background immunosuppressant. The protocol calls for forced vital capacity change from baseline at week 48 as the primary endpoint and the KSQ-Lung score as the key secondary endpoint.

Future Development Requires Additional Capital

The company also identified risks involving patient enrollment, FDA interactions, future study results and its ability to raise the required funding.